Key terms
About BPTH
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BPTH news
Apr 19
12:18pm ET
Bio-Path announces closing of $1.2M registered direct offering
Apr 18
2:00pm ET
Bio-Path announces $1.2M registered direct offering priced at-the-market
Apr 18
7:09am ET
Bio-Path announces completion of higher dose second cohort in trial of BP1002
Apr 15
7:04am ET
Bio-Path expands global patent portfolio
Apr 02
4:23pm ET
Bio-Path Holdings Announces 2024 Clinical and Operational Progress
Apr 02
7:06am ET
Bio-Path provides 2024 clinical, operational update
Mar 27
8:05am ET
Bio-Path price target raised to $40 from $12 at Roth MKM
Mar 12
2:14pm ET
Bio-Path Holdings trading resumes
Mar 12
2:09pm ET
Bio-Path Holdings trading halted, volatility trading pause
Mar 08
5:16pm ET
Bio-Path files to sell 1.15M shares of common stock, warrants
Mar 08
7:02am ET
Bio-Path reports FY23 EPS ($33.63) vs ($38.12) last year
Feb 23
7:12am ET
Bio-Path Holdings Announces Consolidating Reverse Stock Split
Feb 22
7:50pm ET
Bio-Path Holdings trading halted, news pending
Feb 21
7:11am ET
Bio-Path announces 1-for-20 reverse stock split
BPTH Financials
Key terms
Ad Feedback
BPTH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BPTH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range